Linc

Linc EBIT Margin

The EBIT Margin (Operating Margin) of Linc (LINC.ST) as of Nov 20, 2026 is -4,357.19 %. In the previous year, EBIT Margin (Operating Margin) was 10.64 M % — a change of -100.04% (lower).

EBIT Margin

-4,357.19 %

YoY

-100.04%

Last updated:

EBIT Margin (Operating Margin) of Linc is 2025 -4,357.19 % . EBIT Margin (Operating Margin) of Linc was 2024 10.64 M % . It decreases by -100.04% lower compared to the previous year.

Linc's operating (EBIT) margin stands at -4,357.2%, down from -897.6% several years earlier.

The Linc EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
5,304.27 SEK
Jan 1, 2019
12,998.96 SEK
Jan 1, 2020
73,993.29 SEK
Jan 1, 2021
-897.61 SEK
Jan 1, 2022
-37,892.28 SEK
Jan 1, 2023
17,771.21 SEK
Jan 1, 2024
10.64 M SEK
Jan 1, 2025
-4,357.19 SEK
The Linc EBIT Margin history
YEAREBIT MarginYoY
-4,357.19 %-100.04%
10.64 M %+59,780.90%
17,771.21 %-146.90%
-37,892.28 %+4,121.48%
-897.61 %-101.21%
73,993.29 %+469.22%
12,998.96 %+145.07%
5,304.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

EBIT Margin (Operating Margin) of Linc is -4,357.19 % in 2025.

EBIT Margin (Operating Margin) of Linc changed from 10.64 M % to -4,357.19 %, representing a -100.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Linc since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Linc with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Linc

All Key Metrics — Linc